B-Cell Lymphoma with Novartis Kymriah, Pediatric
Kymriah, developed by Novartis, is a type of immunotherapy for pediatric patients with B-Cell Lymphoma. Through Kymriah therapy, a patient's T-cells are genetically reprogrammed to fight cancer cells.
2 Result(s)
Distance
13 Miles
2252 Miles
Details